ALPHARETTA, Ga., Oct. 19, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas Crawford, CSCP, as Vice President, Supply Chain.
Mr. Crawford will be responsible for establishing and managing Clearside’s global supply chain for clinical testing, training and, if approved, trade distribution of suprachoroidal CLS-TA, the company’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space.
In a career spanning more than 25 years, Mr. Crawford has extensive expertise in supply chain management, trade relations, product launches, and manufacturing operations. Before joining Clearside, he was Vice President of Supply Chain and Customer Service for Pharma Tech Industries, LLC, the world’s largest pharmaceutical contract manufacturer and packager of powder products. Mr. Crawford’s earlier experience includes supply chain, manufacturing and trade relations management roles at various pharmaceutical and medical device companies, including Shionogi Inc., Immucor Inc., Aronex Pharmaceuticals Inc., Allergan, Inc., Abbot Laboratories and Zenith Goldline Pharmaceuticals, Inc.
“Thomas brings an important depth of manufacturing operations and supply chain management experience to the company,” said Clearside’s Chief Executive Officer and President, Daniel White. “Thomas will be in a position to provide seamless distribution management for suprachoroidal CLS-TA to many of our global testing sites and, if suprachoroidal CLS-TA is approved, in support of our commercial supply.”
About Clearside
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. The company’s unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations. Clearside’s pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis, retinal vein occlusion (“RVO”) and diabetic macular edema (“DME”). Clearside’s most advanced program is in non-infectious uveitis and it expects to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for use of suprachoroidal CLS-TA for the treatment of macular edema associated with non-infectious uveitis by the end of 2018. The company is also conducting two ongoing Phase 3 trials of suprachoroidal CLS-TA with an intravitreal anti-VEGF agent in patients with RVO. In addition, Clearside recently announced positive topline results from a Phase 2 clinical trial of suprachoroidal CLS-TA used with Eylea® (aflibercept) in patients with DME, and is continuing to analyze additional data from the trial as it becomes available. Clearside is headquartered in Alpharetta, GA. For more information, please visit http://www.clearsidebio.com. Follow @clearsidebio on Twitter and Linkedin.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of Clearside’s product candidates, and the timing of a potential submission of an NDA with the FDA. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 16, 2018, and Clearside’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Stephen Kilmer
Investor Relations
(678) 430-8206
stephen.kilmer@clearsidebio.com
Charles Deignan
Chief Financial Officer
(678) 270-4005
charlie.deignan@clearsidebio.com
Source: Clearside Biomedical, Inc.
